Hims vs Henry Meds for GLP-1 Weight Loss: Brand vs Budget in 2026
An independent, side-by-side comparison of Hims and Henry Meds for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.

Quick Verdict
Best Price
Henry Meds
Starting at $149/mo vs $199/mo
Most Medications
Hims
2 medications vs 2
Best for Beginners
Hims
Async Telehealth, fast onboarding
Head-to-Head Comparison
Pricing Breakdown
Side-by-side pricing for every medication.
| Medication | Hims | Henry Meds | Savings |
|---|---|---|---|
| Semaglutide | $199/monthly | $149/monthly | Save $50/mo with Henry Meds |
| Tirzepatide | $399/monthly | $349/monthly | Save $50/mo with Henry Meds |
Pros and Cons
Hims
- Publicly traded company with financial transparency
- Massive scale — millions of customers across health verticals
- Both compounded and brand-name options
- Free provider consultations included
- No video consultations
- No lab testing included
- GLP-1 only — no other peptides
- Compounded medication availability may vary by state
Henry Meds
- Among the lowest compounded GLP-1 pricing available
- Fast onboarding process (prescriptions within 24-48 hours)
- No consultation fee
- Free shipping included
- Async-only — no video consultations
- No lab testing included
- Relatively new company with limited track record
- Only compounded medications (no brand-name options)
How They Compare
Our editorial assessment across key dimensions.
In-Depth Comparison
By sarah-chen · Last updated April 15, 2026
Hims vs Henry Meds for GLP-1 Weight Loss (2026)
Hims and Henry Meds both provide compounded semaglutide and tirzepatide through cash-pay telehealth. The difference is brand positioning: Hims is a consumer wellness brand with polished packaging, app experience, and men's health ecosystem; Henry Meds is a clinical-first GLP-1 specialist that competes primarily on price. The question is whether Hims' premium is justified by its additional value.
Quick Comparison
| Hims | Henry Meds | |
|---|---|---|
| Monthly cost | ~$199/month | ~$149 (months 1–3), ~$129 thereafter |
| Annual cost | ~$2,388 | ~$1,614 ($149×3 + $129×9) |
| Annual savings vs Hims | Baseline | ~$774/year |
| Compounded semaglutide | Yes | Yes |
| Compounded tirzepatide | Yes | Yes |
| Coaching | Limited | Minimal |
| App experience | Polished consumer app | Functional |
| Men's health ecosystem | Yes — hair loss, ED, mental health | No |
| Women's health | Hers (separate brand) | Unspecified |
| Insurance navigation | No | No |
| Brand-name GLP-1 | Not primary | Not primary |
The Price Gap: What It Means Over Time
| Period | Hims | Henry Meds | Monthly Savings (Henry) |
|---|---|---|---|
| Month 1–3 | $199 | $149 | $50 |
| Month 4–12 | $199 | $129 | $70 |
| Year 1 total | $2,388 | $1,614 | $774 |
| Year 2 total (at loyalty rate) | $2,388 | $1,548 | $840 |
| 2-year total | $4,776 | $3,162 | $1,614 |
Over two years on GLP-1, Henry Meds saves approximately $1,600 vs Hims — a meaningful amount for what is likely a multi-year medication commitment.
What Hims Offers That Henry Meds Doesn't
| Feature | Hims | Henry Meds |
|---|---|---|
| Polished app and packaging | Yes — consumer-grade UX | No — clinical focus |
| Men's health consolidation | Hair loss + ED + mental health in same app | Weight loss only |
| Brand trust and recognition | High for men 25–45 | GLP-1 specialist audience |
| Multi-condition subscription | Yes | No |
The Hims premium buys: app experience, brand trust for patients who prefer recognizable consumer brands, and the convenience of having multiple men's health concerns in one platform.
What Henry Meds Offers That Hims Doesn't
| Feature | Henry Meds | Hims |
|---|---|---|
| Loyalty pricing after 3 months | $129/month | Stays at $199 |
| GLP-1 clinical focus | Yes — specialty | One product among many |
| Lower total cost | $1,614/year | $2,388/year |
Henry Meds competes on value for patients who want the medication at the lowest responsible price from a dedicated GLP-1 platform.
Clinical Equivalence: Same Medication, Different Wrapper
Both Hims and Henry Meds provide compounded semaglutide or tirzepatide from third-party compounding pharmacies. The active medication is clinically equivalent — the prescription and compounding pathway is similar.
Neither provides:
- Insurance navigation
- Brand-name GLP-1 access pathway
- Integrated lab review
- Structured behavioral program
Clinical outcomes depend primarily on the medication, not the platform wrapper — which means the price difference is the primary decision variable for most patients.
Who Each Platform Serves Best
Hims is better if you:
- Are a man already using Hims for other health needs (hair loss, ED) and want convenience consolidation
- Value polished consumer UX and brand trust
- Are willing to pay a premium for the Hims ecosystem and experience
- Don't mind the ongoing $199/month with no loyalty discount
Henry Meds is better if you:
- Want the lowest sustainable monthly cost for compounded GLP-1
- Prefer a platform focused specifically on GLP-1 and weight management
- Are on GLP-1 long-term and want the $70–80/month loyalty savings
- Don't need or use other Hims health products
Related Resources
- Henry Meds GLP-1 Review — full program review
- Hims Weight Loss Review — full program review
- Henry Meds vs Hims GLP-1 — same comparison, different entry angle
- Best Cash-Pay GLP-1 Programs — full ranking
Related Guides
Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →Is Compounded Semaglutide Legal and Safe in 2026?
Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.
Read guide →Compounded Tirzepatide 2026: What's Happening and What Patients Should Do
Compounded tirzepatide is under active FDA enforcement as of March 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in March 2026. Here's what patients need to know and what to do.
Read guide →